Skip to main content

WIPO eTISC

WIPO eTISC is a social platform which provides a secure space for the Technology and Innovation Support Center (TISC) community and intellectual property (IP) users to interact with each other and share knowledge and ideas.

Sign into eTISC

To access the full features and services of eTISC, please sign in with a WIPO account or create an account.

By accessing/using the eTISC platform, the user is agreeing to be bound by these Terms of Use.

Webinar: Participation models for spinouts

Go Back

Webinar: Participation models for spinouts

Submitted by Efua Halm
-
Time Zone
Europe/Zurich
Expert Name

What is a spinout company? Why form one and who gets equity in it once it is formed? What are the stakes and who owns what? Who are the players in this context and how does everyone fit together? So many questions but often few answers arise.  

For our sixth session in our series of webinars delving into IP valuation and IPRs management, we are thrilled to bring to you a session focused on ‘Participation models for spinouts’. Our expert, Dr. Mohammed Aljafari, Director, IP Commercialization Office, iPARK - Royal Scientific Society, Amman, Jordan, will join us to flesh out the possible options that can be taken on the critical commercialisation journey.  

Date: Monday, 26th September, 2022 @ 10am CEST (Central European Summer Time) 

Register @: https://www.wipo.int/meetings/en/details.jsp?meeting_id=73308 

Meet your expert:

 

Dr Aljafari is the Director of the Intellectual Property Commercialization Office at iPARK, the Royal Scientific Society. He is a strategy, industry, investment, entrepreneurship, IP, innovation, and finance professional. With more than 20 years of experience in Innovation, he has engineered and successfully executed technological alliances across multiple sectors.

Dr Aljafari is a member of numerous technical and advisory boards at academic and private institutions worldwide and was one of the experts tasked with drafting the WIPO model on IP policy for research and academic institutions.

He has a PhD in Pharmaceutical Sciences from Nottingham University, UK.

Add Comment